Localized Gastric MALT Lymphoma When First-Line H. pylori Eradication Therapy Has Failed
Clinical Scenario
Early-stage, H. pylori-positive gastric MALT lymphoma in a patient whose initial antibacterial eradication regimen did not achieve the expected treatment goals confirmed at endoscopic follow-up.
Prior Line — Failure Condition
The first-line approach used triple therapy combining a proton-pump inhibitor (PPI) with clarithromycin and either amoxicillin or metronidazole. When endoscopy at 3 to 6 months after treatment confirmed that neither H. pylori eradication nor complete remission of the gastric MALT lymphoma had been achieved, this protocol becomes the next step.
Treatment Approach — Partial Overview
For patients whose initial therapy has failed, an alternative triple antibiotic regimen incorporating levofloxacin is among the options used. The full protocol — including the complete combination, clinical criteria, and sequencing — is available via the link below.
Treatment Goals
Eradication of H. pylori infection and complete remission of the gastric MALT lymphoma, verified by endoscopy.
References
- Until now, the most widely accepted initial treatment option for localized disease is the eradication of H pylori using the triple therapy based on the combination of proton-pomp inhibitors (PPI), clarithromycin with either amoxicillin or metronidazole for 10 to 14 days.
- Several studies have confirmed the effectiveness of antibiotic therapy with long-term remissions in 70% to 100% of patients with localized, H pylori-positive, MALT lymphomas.
- Similarly, levofloxacin has been used in patients whose initial triple therapy had failed.
- In this case, triple therapy would include levofloxacin, amoxicillin, and a PPI for 14 days.
- To assess MALT lymphoma remission, a first endoscopy is performed 3 to 6 months after completion of antibacterial treatment, which also allows for checking of the H pylori status histologically.
View source ↗